To further evaluate dominant mutational clones in non-APL AML, we defined a mutation as dominant when either (1) it was the sole mutation detected (e.g., WT1, DNMT3A, or FLT3 in three patients each) or (2) it displayed a variant allele frequency (VAF) at least 10% higher than other co-occurring mutations. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.